NXTC
NextCure, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
NextCure has 6 disclosed suppliers and 1 disclosed customer in SEC filings.
Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied
SentenceLNCB74 is being advanced under a November 2022 Research Collaboration and Co-Development Agreement (the "LigaChem Agreement") with LigaChem Biosciences, Inc., formerly known as LegoChem Biosciences, Inc ("LigaChem").
NXTC 10-Kaccession 0001104659-26-024137
SentenceLNCB74 is being advanced under a November 2022 Research Collaboration and Co-Development Agreement (the "LigaChem Agreement") with LigaChem Biosciences, Inc., formerly known as LegoChem Biosciences, Inc ("LigaChem").
NXTC 10-Kaccession 0001104659-26-024137
SentenceWe obtained (1) an exclusive, worldwide (excluding the Zaiming Territory, as identified below) license to develop, manufacture, and commercialize Zaiming's clinical-stage ADC candidate, SIM0505, and related compounds (the "Zaiming Products"), and (2) a non-exclusive, worldwide (excluding the Zaiming Territory) license to use Zaiming's ADC platform technology to develop ADCs based on the Company's proprietary antibodies for an additional novel target (the "NextCure Products") ("the License agreement").
NXTC 10-Kaccession 0001104659-26-024137
SentenceFor example, WuXi XDC, which is currently the only CDMO we use to conjugate our B7-H4 antibody and produce LNCB74 ADC drug product, is affiliated with WuXi AppTec.
NXTC 10-Kaccession 0001104659-26-024137
SentenceWe are party to a license agreement with Yale University under which we acquired rights to intellectual property related to certain of our product candidates.
NXTC 10-Kaccession 0001104659-26-024137
SentenceOur product candidate SIM0505 is a novel ADC candidate developed by Zaiming, to which we acquired the global rights (excluding China, Hong Kong, Macau and Taiwan) to develop, manufacture, and commercialize under the License Agreement, dated June 13, 2025, between the Company and Zaiming.
NXTC 10-Kaccession 0001104659-26-024137
SentenceIn connection with the License Agreement, the Company also entered into a Subscription Agreement (the "Subscription Agreement") pursuant to which the Company issued and sold to Simcere Zaiming, Inc. ("Simcere Zaiming"), a Delaware corporation and an affiliate of Zaiming, in a private placement, an aggregate of 338,636 shares (the "Shares") of the common stock of the Company, par value $0.001 per share, at a price of approximately $5.904 per Share for an aggregate purchase price of $2.0 million.
NXTC 10-Kaccession 0001104659-26-024137
NextCure, Inc.
6.18
Largest filed tie
—
Expected move
No implied move.